Market capitalization | $32.80m |
Enterprise Value | $110.00k |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.00 |
P/S ratio (TTM) P/S ratio | 0.77 |
P/B ratio (TTM) P/B ratio | 1.46 |
Revenue growth (TTM) Revenue growth | 26.25% |
Revenue (TTM) Revenue | $42.62m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
4 Analysts have issued a Equillium, Inc. forecast:
4 Analysts have issued a Equillium, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 43 43 |
26%
26%
|
|
Gross Profit | 42 42 |
26%
26%
|
|
EBITDA | -9.58 -9.58 |
49%
49%
|
EBIT (Operating Income) EBIT | -9.71 -9.71 |
49%
49%
|
Net Profit | -8.32 -8.32 |
54%
54%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Equillium, Inc. is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.
Head office | United States |
CEO | Bruce Steel |
Employees | 44 |
Founded | 2017 |
Website | www.equilliumbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.